- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GZR-18, Placebo
- Drug · Other
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1633–1656
of 4,220
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophilic Asthma
- Interventions
- ICS-LABA, benralizumab, Placebo for Benralizumab
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- NX-1207, Placebo
- Drug
- Lead sponsor
- Nymox Corporation
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 35
- States / cities
- Laguna Hills, California • San Diego, California • Tarzana, California + 30 more
- Conditions
- Alcohol Use Disorder, Obesity and Overweight, Alcohol
- Interventions
- Tirzepatide, Placebo injections
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glabellar Frown Lines (GL)
- Interventions
- EB-001 injection, Placebo injection
- Drug
- Lead sponsor
- Bonti, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Fremont, California • Newport Beach, California
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lupus Nephritis
- Interventions
- zetomipzomib, placebo
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- LAD603, Placebo
- Drug · Other
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Interventions
- AV-001 Injection, AV-001 Placebo Injection
- Drug
- Lead sponsor
- Vasomune Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Denver, Colorado • Chicago, Illinois + 3 more
- Conditions
- Pelvic Organ Prolapse
- Interventions
- Bupivacaine, Placebo
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Pracinostat, Placebos, Azacitidine
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
- Interventions
- HGF plasmid, Placebo
- Genetic
- Lead sponsor
- AnGes USA, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
- Conditions
- Non-Diabetic
- Interventions
- REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Prostate Carcinoma
- Interventions
- Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 115
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
- Conditions
- Cicatrix
- Interventions
- Juvista (avotermin)
- Drug
- Lead sponsor
- Renovo
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 9,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Interventions
- ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, 100 mg PF-05231023
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida
- Conditions
- Subcutaneous Fat
- Interventions
- CBL-514 Injection, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more
- Conditions
- Alopecia Areata
- Interventions
- JNJ-64304500, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
- Conditions
- Myofascial Pain Syndromes, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
- Interventions
- OnabotulinumtoxinA, Placebo
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Mayfield Heights, Ohio • Westlake, Ohio
- Conditions
- Peripheral Vascular Diseases
- Interventions
- riferminogene pecaplasmid, Placebo (for riferminogene pecaplasmid)
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Tirzepatide, Placebo (saline)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more